drugset / Trial / NCT02037425
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine
NaSingle-groupOpen-labelTreatment
Summary
To obtain a patient specific understanding of response to treatment with onabotulinumtoxinA by collecting and correlating pre and post treatment subject specific history, clinical outcomes, and histological changes.
Timeline
- Start
- 2014-04
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 155 iu | — |